Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Rilzabrutinib Fast Track Designation for Immune Thrombocytopenia

November 18th 2020

November 18, 2020 - The FDA has granted a fast track designation to the BTK inhibitor rilzabrutinib for the treatment of patients with immune thrombocytopenia.

The Future of MDS Management

November 18th 2020

Overview of Luspatercept-aamt as MDS Treatment

November 18th 2020

The Role of Hypomethylating Agents and Transplantation

November 18th 2020

Initiating First-Line Treatment

November 18th 2020

The Role of Supportive Care

November 18th 2020

IPSS/IPSS-R Reliability in Various Disease Settings

November 18th 2020

Disease-Course Differentiation: Low Risk and High Risk

November 18th 2020

Challenges of MDS Management

November 18th 2020

Ensuring an Accurate Diagnosis

November 18th 2020

Heterogeneity and Presentation of MDS

November 18th 2020

COVID-19 Delays FDA Review of Liso-Cel for Relapsed/Refractory Large B-Cell Lymphoma

November 17th 2020

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

NICE Recommends Caplacizumab for Acute Acquired Thrombotic Thrombocytopenic Purpura

November 16th 2020

November 16, 2020 — The United Kingdom’s National Institute for Health and Care Excellence has recommended caplacizumab-yhdp with plasma exchange and immunosuppression for the treatment of an acute episode of acquired thrombotic thrombocytopenic purpura in adults and those aged 12 years and over who weigh at least 40 kg.

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes

November 14th 2020

Deepa Jagadeesh, MD, discusses unmet needs in aggressive and rare lymphoma subtypes.

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

November 8th 2020

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

The Future of CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

November 6th 2020

Impact of COVID-19 on CAR T-Cell Therapy for R/R DLBCL

November 6th 2020

Real-World Data for CAR T-Cell Therapy for R/R DLBCL

November 6th 2020

CAR T-Cell Therapy Clinical Trials for R/R DLBCL

November 6th 2020

Mechanism of CAR T Cells in R/R Diffuse Large B-Cell Lymphoma

November 6th 2020